






The last several years have seen an increased interest in the use of induced hypothermia after witnessed cardiopulmonary 
resuscitation (CPR). The main reason for its use is protection of the brain and hence, better neurological outcome in 
these patients. Therefore, induced hypothermia after CPR has become a part of standard recommendations in the 2005 
Resuscitation Guidelines. At the same time, hypothermia can have many adverse effects. In the event of pre-hospital and/or 
in-hospital induction of hypothermia, without adequate monitoring and controlled cooling, hypothermia can cause serious 
complications, without beneficial effects on the brain. This article explains the most frequent adverse effects of hypothermia 
and possible hazardous outcomes for patients.
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Interest in hypothermia for neuropro-
tection began in the 1980s. For some 
surgical procedures, primary cardiac 
and neurosurgical, hypothermia can 
be used for conservation of brain tis-
sue and decreasing cerebral metabolic 
oxygen rate (CMRO2). States of strongly 
controlled and deep hypothermia are 
usually achieved using cardiopulmonary 
bypass devices and neuroprotective 
agents combined with brain monitoring. 
The last several years have seen an 
increased interest in the use of induced 
hypothermia after witnessed cardiopul-
monary resuscitation (CPR). The main 
reason for its use is to protect the brain 
against irreversible hypoxic damage 
and hence, to achieve better neuro-
logical outcomes in these patients. For 
these reasons, induced hypothermia 
after CPR has became a part of the 
2005 Guidelines for Resuscitation (1). 
Clinical purpose
By definition, hypothermia is a body 
temperature less than 36 oC and it is 
divided into three stages: mild hypo-
thermia, when the body temperature is 
between 35 oC-32 oC, moderate hypo-
thermia when the body temperature is 
between 32 oC and 30 oC, and deep 
hypothermia when the body tempera-
ture is less than 30 oC. Methods for 
decreasing core temperature have var-
ied. In animal studies, cardiopulmonary 
bypass, cold aortic flush, external cool-
ing and peritoneal cooling are some 
examples of the methods that have 
been used. Clinical studies have been 
performed using external cooling with 
icepacks, forced cooled air or a cool-
ing helmet device or by using a rapid 
(30 min) intravenous infusion of a large 
volume (30 ml/kg) of lactated Ring-
er’s solution, cooled at 4 oC. The main 
problem with all of these methods is 
the slow decrease in core temperature. 
The measured drop in temperature was 
between 0.3 oC/h for forced cooled air 
(2), 0.9 oC/h for icepacks (3), and the 
highest decrease in core temperature 
(1.7 oC) was reached with fluid admin-
istration (3). All of the above mentioned 
methods do not provide a quick and 
safe means of decreasing core tem-
perature. In pre-hospital and/or in-hos-
pital induction of hypothermia, without 
adequate monitoring and controlled 
cooling, hypothermia can cause seri-
ous complications, without beneficial 
effects on the brain.
Adverse effects of hypo-
thermia on the heart and 
hemodynamics
The adverse effects of hypothermia 
mainly disturb heart function and func-
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tion of the vascular system. It is known 
that more than 80% of all cardiac arrests 
are caused by presumed cardiac dis-
ease, of which more than 60% of adult 
deaths result from coronary heart dis-
ease (4). According to these data, car-
diac and hemodynamic disturbances 
are augmented by hypothermia. Firstly, 
after return of spontaneous circulation 
(ROSC), following ventricular fibrillation, 
the myocardium shows huge electrical 
and mechanical instability. This instabil-
ity may cause refibrillation within a short 
time after ROSC. Refibrillation is espe-
cially dangerous if cooling starts imme-
diately after ROSC and if performed 
by emergency medical personnel, as 
reported by Nolan et al (5), and Bernard 
et al (3). In comparison with normother-
mic myocardium, the fibrillating hypo-
thermic myocardium is characterized 
by increased contraction amplitude (6), 
decreased contraction velocity (6) and a 
decreased median fibrillation frequency 
(7). These characteristics of the fibrillat-
ing hypothermic heart may contribute to 
a reduced efficiency of electrical coun-
ter shock therapy, as observed in both 
experimental animals and humans (8-
10). Electrophysiological changes asso-
ciated with ischemia are similar to those 
induced by hypothermia (11). As men-
tioned earlier, most cardiac arrests are 
a consequence of myocardial ischemia. 
Thus ischemia may potentiate the 
arrhythmogenic potential of hypothermia 
(11). Improving myocardial perfusion by 
increasing coronary perfusion pressure 
(CPP) may reverse some of the elec-
trophysiological changes and improve 
the outcome of CPR. This increase in 
CPP was associated with a significant 
improvement in defibrillation success 
(12). To improve CPP it is necessary 
to involve vasoactive drugs. In a state 
of post CPR instability, these agents 
can also provoke malignant arrhythmi-
as. These agents increase myocardial 
oxygen consumption, what in a state 
of compromised coronary circulation, 
can worsen myocardial ischemia and 
enlarge the infarction zone. On the other 
hand, it is known that receptors for ino-
tropes and vasoactive drugs become 
unresponsive during hypothermia and 
that the action of these drugs shifts from 
the heart to the vasculature producing 
an undesirable increase in peripheral 
vascular resistance.
In one of the first studies about induced 
hypothermia, Bernard et al (3) had sig-
nificantly higher values of systemic vas-
cular resistance and lower values of 
cardiac index in a group of patients with 
hypothermia throughout the whole 24 
hour period of treatment compared with 
patients in normothermia. This unfa-
vourable effect was not commented 
on and outcome, according to their 
cardiac function after induced hypo-
thermia, was not evaluated. Further-
more, in the same study, patients with 
induced hypothermia received much 
more epinephrine infusions. 
In a newer study by Kliegel et al (13), 
was instilled 2000 mL of ice-cold infu-
sions cooled to 4 oC via an endovas-
cular catheter. The only hemodynamic 
monitoring was invasive arterial pres-
sure monitoring. Except for 3 patients, 
all other patients had a cardiac event 
due to acute coronary syndrome (ACS). 
Unfortunately, there is no data on cen-
tral venous pressures (CVP) and/or 
changes in pulmonary artery pressures 
during the cooling process with high 
doses of infusions. During ACS, espe-
cially with acute left ventricular myo-
cardial infarction, the main problem 
is decreasing left ventricular compli-
ance and diastolic dysfunction. These 
patients are very vulnerable to volume 
overload and rapidly develop pulmo-
nary edema, which happened in this 
study in 7% of patients. There is no evi-
dence in this study as to the reasons for 
pulmonary edema in these patients. 
Adverse effects of hypo-
thermia on other organs 
and organ systems
There are many adverse effects of hypo-
thermia on the functioning of organs 
and organ systems. Firstly, hypothermia 
impairs immune function and leads to 
nosocomial pneumonia. Secondly, hypo-
thermic patients with a core temperature 
1.5 oC - 2.0 oC below normal (35.5 oC- 
35.0 oC) have an approximately 19% rate 
of infection as opposed to a 6% rate of 
infection in normothermic patients. These 
findings may be a result of the fact that 
hypothermia increases a patients’ vulner-
ability caused by vasoconstriction and 
impaired immunity. In a large European 
study (2) the incidence of sepsis was 
almost twofold higher in the group of 
patients randomised to hypothermia than 
in normothermic patients (7% vs. 13%).
The risk of infection can be augmented 
by poor glycemic control. An impor-
tant side effect is insulin resistance 
and decreased insulin release. Other 
adverse effects in the gastrointestinal 
system are decreased gastrointestinal 
motility, raised serum amylase and liver 
enzymes which can produce metabolic 
acidosis as a result of increased lactate 
concentrations and increased produc-
tion of free fatty acids, ketones and 
glycerol.
Intracellular movements of potassium, 
magnesium, and phosphate during 
hypothermia lead to lowered serum 
concentrations of these anions and 
may produce serious arrhythmias. 
Hypothermia has several negative 
effects on the hematological system. 
Bleeding time is lengthened as a result 
of reduction in the number and function 
of platelets sequestered by the spleen 
and liver. The coagulation cascade may 
also be impaired, white cell count also 
decreases and their movement is also 
impaired.
Hypothermia produces significant 
altered actions of many drugs com-
monly used during the post-resuscita-
tion period. The action of many agents 
used in CPR may be ineffective or occur 
with delayed action. Lidocaine has no 
documented beneficial effects during 
hypothermia. Clinical data suggest 
that amiodarone has an immediate 
antiarrhythmic effect, present already 
a few minutes after intravenous bolus 
administration (14,15), but in the state 
of hypothermia, amiodarone had no 
beneficial effects on the resuscibilty of 
the fibrillating hypothermic heart (12). In 
a state of hypothermia, non-depolariz-
ing muscle relaxants with a predictable 
half-life, prolong their average duration 
of action more than double, with an 
unpredictable time of action. 
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Conclusion
The main reason why inducing hypo-
thermia is now included in the new rec-
ommendations for CPR is to decrease 
the risk of hypoxic brain damage. 
Unfortunately, hypothermia may often 
cause very serious adverse effects or 
complications, which can be hazard-
ous for the patient. 
Many studies today, looking at induced 
hypothermia after CPR, are orientated 
exclusively on the neurological outcome 
of patients. In many of these studies 
there is no, or only very weak, evidence 
concerning functions and adverse 
effects of hypothermia on other organs 
or organ systems. Clinical follow-up of 
primary heart functioning after arrest 
is not well documented. Changes in 
hemodynamics during the first 24 hours 
after ACS may produce deleterious con-
ditions for the patients, especially if rela-
tively uncontrolled measures of cooling 
are used. Induction of core hypother-
mia using surface cooling blankets is a 
relatively slow process, especially when 
patients are vasoconstricted (16,17). On 
the other hand, the use of large amounts 
of ice-cold (4 oC) volume can decrease 
core temperature rapidly, but may be 
very hazardous in patients with unstable 
heart function and rhythm, and, finally, 
may cause depletion of platelets, leuko-
cytes and impair coagulation function.
From all the studies, it is not clear in 
which real time it is best to perform 
induced hypothermia to achieve opti-
mal neuroprotection. Data shows very 
different times from ROSC to applying 
hypothermia, regardless if it was start-
ed by emergency medical personnel 
on the field or by staff in the emergency 
departments/intensive care units. 
In general, the use of induced hypother-
mia after CPR could be very danger-
ous if is not well controlled, especially 
if established in pre-hospital condi-
tions. The final outcome, unfortunately, 
could be much more undesirable for 
the patient compared to the minimal 
improvement in neurological state.
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